当地时间2024年8月31日,在欧洲心脏病学会(ESC)年度大会上,一项题为“Long-term Outcomes of Intensive Blood-Pressure Control in Older Patients with Hypertension: Final Six-year Results of the STEP Trial”的大型临床研究正式发布了...
9月1日,在ESC 2024大会上公布了MAVA-LTE研究的EXPLORER-LTE队列最长随访时间达3.5年的结果,这也是迄今为止随访时间最长的玛伐凯泰研究数据,为玛伐凯泰的长期疗效及安全性提供强有力的循证支持。该研究结果显示,梗阻性HCM患者的超声心动...
3、中南大学湘雅二医院心血管内科周胜华教授团队完成、主要研究者肖宜超副研究员报告了一项题为“Effects of Intensive vs Standard Blood Pressure Control on Cardiovascular Outcomes in Cancer Survivors: Results from the SPRINT Randomized Trial”的大型临床研究结果 研究背景 随着全球癌症生存率的不断提高，心血管疾病...
ESC 2024热点速递,新证据显示玛伐凯泰3.5年持续获益 MAVA-LTE研究是一项计划随访期为5年的研究。9月1日,在ESC 2024大会上公布了MAVA-LTE研究的EXPLORER-LTE队列最长随访时间达3.5年的结果,这也是迄今为止随访时间最长的玛伐凯泰研究数据,为玛伐凯泰的长期疗效及安全性提供强有力的循证支持。该研究结果显示,梗阻性H...
16. DG Gaudet, et al. Transition of patients with familial chylomicronaemia syndrome from volanesorsen to olezarsen: safety and pharmacokinetic results. Presented at Moderated ePosters, 1 September, ESC Congress 2024. 17. Z Xie, et al. SHR-1918, a monoclonal antibody against angiopoietin-like...
湘雅二医院周胜华教授团队临床研究在ESC2024发布结果 当地时间2024年8月31日,在欧洲心脏病学会(ESC)年度大会上,一项题为“基于SPRINT研究肿瘤幸存者强化降压对心血管预后的影响”(Effects of Intensive vs Standard Blood Pressure Control on Cardiovascular Outcomes in Cancer Survivors: Results from the SPRINT ...
6. P Gargiulo, et al. Efficacy and safety of inclisiran in real-world clinical practice. Results from the CHOLINET Registry. Presented at Moderated ePosters, 31 August, ESC Congress 2024. 7. Sustained LDL-C reduction: from long-term trials to real-world implementation. Presented at Satellite...
[12].Comparison Of An “Inclisiran First” Strategy With Usual Care In Patients With Atherosclerotic Cardiovascular Disease: Results From The VICTORION-INITIATE Randomized Tria. Presented at ACC2024. [13].Koren MJ, Rodriguez F, East C, Toth PP, Watwe V, Abbas CA, Sarwat S, Kleeman K, Ku...
[8] Ling Tao, et al. One-month DAPT followed by 5-month Ticagrelor monotherapy in acute coronary syndromes with DCB – results from REC-CAGEFREE II. Presented at: EuroPCR 2024 [9] U. Zeymer, et al . SENIOR RITA - Invasive versus Conservative Strategy for Older Patients with Myocardial ...
[7]. HELIOS-B - Primary results from phase 3 study of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. 2024 ESC 本材料由阿斯利康提供，旨在满足您的医学信息需求，仅供医疗卫生专业人士参考，不用于推广目的。审批编码：CN-142776 过期日期：2025-8-30 （转自：医学界）